Abstract

Stress-induced disturbances of brain homeostasis and neuroinflammation have been implicated in the pathophysiology of mood disorders. In major depressive disorder (MDD), elevated levels of proinflammatory cytokines and chemokines can be found in peripheral blood, but very little is known about the changes that occur directly in the brain. Microglia are the primary immune effector cells of the central nervous system and exquisitely sensitive to changes in the brain microenvironment. Here, we performed the first single-cell analysis of microglia from four different post-mortem brain regions (frontal lobe, temporal lobe, thalamus, and subventricular zone) of medicated individuals with MDD compared to controls. We found no evidence for the induction of inflammation-associated molecules, such as CD11b, CD45, CCL2, IL-1β, IL-6, TNF, MIP-1β (CCL4), IL-10, and even decreased expression of HLA-DR and CD68 in microglia from MDD cases. In contrast, we detected increased levels of the homeostatic proteins P2Y12 receptor, TMEM119 and CCR5 (CD195) in microglia from all brain regions of individuals with MDD. We also identified enrichment of non-inflammatory CD206hi macrophages in the brains of MDD cases. In sum, our results suggest enhanced homeostatic functions of microglia in MDD.

Details

Title
Single-cell mass cytometry of microglia in major depressive disorder reveals a non-inflammatory phenotype with increased homeostatic marker expression
Author
Böttcher Chotima 1   VIAFID ORCID Logo  ; Fernández-Zapata Camila 1   VIAFID ORCID Logo  ; Snijders Gijsje J L 2 ; Schlickeiser Stephan 3 ; Sneeboer Marjolein A M 4 ; Kunkel Desiree 5 ; De Witte Lot D 6 ; Priller Josef 7 

 Charité – Universitätsmedizin Berlin, Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662) 
 Brain Center Rudolf Magnus, University Medical Center Utrecht, Department of Psychiatry, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352) 
 BIH Center for Regenerative Therapies (BCRT), Charité – Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662) 
 Brain Center Rudolf Magnus, University Medical Center Utrecht, Department of Psychiatry, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352); Icahn School of Medicine at Mount Sinai, Department of Psychiatry, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351) 
 Flow & Mass Cytometry Core Facility, Charité – Universitätsmedizin Berlin and Berlin Institute of Health (BIH), Berlin, Germany (GRID:grid.484013.a) 
 Brain Center Rudolf Magnus, University Medical Center Utrecht, Department of Psychiatry, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352); Icahn School of Medicine at Mount Sinai, Department of Psychiatry, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351); Mental Illness Research, Education and Clinical Center (MIRECC), James J Peters VA Medical Center, Bronx, USA (GRID:grid.274295.f) (ISNI:0000 0004 0420 1184) 
 Charité – Universitätsmedizin Berlin, Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); DZNE and BIH, Berlin, Germany (GRID:grid.6363.0); University of Edinburgh and UK Dementia Research Institute (DRI), Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
21583188
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2471520207
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.